Key facts
- Atsena Therapeutics’s last known valuation is $340.0M (Apr 2025).
- It has raised $237.7M across 4 recorded rounds; the latest was Later Stage VC ($90.0M) in Mar 2025.
- Notable investors include Wellington Management, Bain Capital, Osage University Partners, Hatteras Venture Partners, Lightstone Ventures — 12 tracked in total.
- Atsena Therapeutics has filed 4 Form Ds with the SEC since 2020, most recently Apr 2025 ($90.0M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Atsena Therapeutics
Funding rounds
4 roundsAbout Atsena Therapeutics
Developer of ocular gene therapies designed to reverse or prevent blindness. The company's programs include treatments for leading forms of Leber congenital amaurosis and Usher syndrome and have a pipeline powered by associated virus technology, enabling healthcare professionals to reverse or prevent blindness and overcome the hurdles presented by inherited retinal disease.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2019
- Employees
- 32
- Website
- atsenatx.com/
- Ownership
- Privately Held (backing)
Atsena Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atsena Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atsena Therapeutics in its N-PORT filings yet. We sweep new filings monthly.